Malignant melanoma is a tumor arising from epidermal melanocytes. It is one of the most frequently occurring malignant tumors in Caucasians. Melanoma is classified into four major primary types, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma (palmoplantar malignant melanoma) and four minor types - subungual melanoma, mucosal melanoma, secondary melanoma from an occult primary site, and multiple primary malignant melanomas. The highly undifferentiated melanoma may produce no melanin granules. The term, amelanotic melanoma, is used loosely for both true amelanotic lesions with no pigmentation and melanomas with minimal residual pigmentation. Most cases of amelanotic melamona are metastatic, but cases of primary amelanotic melanoma have been reported.
This chapter defines amelanotic melanoma and reviews the clinical and histopathological features. This chapter also provides a basic review of melanogenesis in melanosomes in the melanocytes as well as describes the uses of immunohistochemical staining for not only diagnosing melanomas but also determining the degree of differentiation of melanoma cells. As the production of melanin granules in melanosomes is distinctly regulated from stages I to IV, immunohistochemical staining may identify the damaged step in melanogenesis, which would indicate the degree of differentiation of melanoma cells in amelanotic melanoma. This chapter is designed to improve understanding of the pathogenesis of amelanotic melanoma, which is not monogeneous but heterogenous.
2. The stage of melanogenesis in amelanotic melanoma
2.1. Amelanotic melanoma
2.1.1. The definition of amelanotic melanoma
Amelanotic melanoma is used for both true amelanotic lesions with no pigmentation and melanomas with minimal residual pigmentation (Wain et al., 2008). Recently, the term “hypomelanotic melanma” is used for melanomas with faint pigmentation (Piccolo et al., 2010; Menzies et al., 2008). The melanoma cells in amelanotic melanoma cannot produce mature melanin granules, resulting in the absence of melanin granules.
2.1.2. The clinical features of amelanotic melanoma
The absence of pigmentation is the main difficulty encountered when clinically diagnosing amelanotic melanoma (Piccolo et. al., 2008). In amelanotic melanoma, the most prevalent clinical and histopathological type is nodular melanoma (Gualandri et al., 2009). The higher Breslow thickness of amelanotic melanoma may be associated with a worse prognosis (Gualandri et al., 2009). Amelanotic melanoma can develop from any type of melanoma, including superficial spreading melanoma (Holder et al., 1996), nodular melanoma (Kanoh et al., 2010; Oiso et al., 2010), lentigo maligna melanoma (Martires et al., 2010), acral lentiginous melanoma (Yasuoka et al., 1999), subungual melanoma (Gosselink et al., 2009; Matsuta et al., 2000), and mucosal melanoma (Khaled et al., 2009; Notani et al., 2002), as well as from primary amelanotic melanoma of the esophagus (Terada, 2009; Wang et al., 2008), cervix (Duggal & Srinivasan, 2010), and colon (Sashiyama et al., 2010).
Common clinical differential diagnoses of amelanotic or hypomelanotic melanoma may include hypomelanotic nevus, Spitz nevus, basal cell carcinoma, seborrhoeic keratosis, dermatofibroma, keratoacanthoma, pyogenic granuloma, haemangioma and Bowen’s disease (Piccolo et al., 2008; Zalaudek et al., 2005; Blum et al., 2004; Ferrari et al., 2004; Zalaudek et al., 2004; Holder et al., 1996; Elmets & Ceilley, 1980).
Most reported cases of amelanotic melanoma are metastatic, but cases of primary lesions also have been described (Wain et al., 2008; Yanagi et al., 2005; Gupta & Lallu, 1997; Holder et al., 1996). Most primary cases are melanomas with minimal residual pigmentation or hypomelanotic melanoma. The depicted figure is a typical case; an 80-year-old Japanese woman having an asymptomatic bulky ulcerated nodule 20 mm in size, with slight pigmentation located peripherally on the left vulva (Oiso et al., 2010) (Fig. 1).
2.1.3. The histopathological features of amelanotic melanoma
Amelanotic melanoma is undifferentiated melanoma with no or few melanin granules. True amelanotic melanomas produce no melanin granules, resulting in no pigmentation, while amelanotic melanomas with minimal residual pigmentation or hypomelanotic melanomas produce a few melanin granules, resulting in some pigmentation in some part of the tumor. The histopathology of the case in Fig. 1 showed amelanotic melanomas with minimal residual pigmentation. One of the specimens had melanoma cells in the epidermis and upper dermis, with infiltration of mononuclear cells as the initial developmental lesion on the left side (Hematoxylin and eosin (HE) staining, ×100) (Fig. 2) (Oiso et al., 2010). Massively proliferated melanoma cells were present in the dermis on the right side (Fig. 2) (Oiso et al., 2010). The melanoma cells from the left side of the specimen had irregular shapes and large hyperchromatic nuclei with melanin granules in the upper dermis (HE, ×400) (Fig. 3) (Oiso et al., 2010). The massively proliferated cells produced no melanin granules in the dermis on the right side (Fig. 3) (Oiso et al., 2010). As shown here, amelanotic melanomas with minimal residual pigmentation have few melanin granules inside the tumor. However, true amelanotic melanomas have no melanin granules. The identification of melanin granules is necessary for a histopathological diagnosis of malignant melanoma other than true amelanotic melanoma.
2.2. Melanogenesis in melanosomes
2.2.1.The stages of melanosomes in melanocytes
Melanin granules are produced in the melanosomes in melanocytes. Each melanosome moves from the perinuclear area towards the dendrites and changes its shape from stage I to stages II, III, and IV. Stage I melanosomes (also called premelanosomes) are relatively
spherical organelles with matrix material (i.e. filaments) that is beginning to assemble; stage II melanosomes are oval-shaped organelles with an organized internal matrix that does not contain melanin; stage III melanosomes are organelles with a matrix that contains deposits of melanin; and stage IV melanosomes are organelles completely filled with melanin (Boissy et al., 2006). Therefore, true amelanotic melanoma may contain stage I and/or II melanosomes, but not stage III and IV melanosomes.
2.3. Immunohistochemical staining
2.3.1. Immunohistochemical staining for diagnosis
Amelanotic melanoma is diagnosed by means of immunohistochemical staining, especially using a panel of melan-A/melanoma antigen recognized by T cells-1 (MART-1), S-100, and HMB-45 (Oiso et al, 2010). In the case shown in Fig. 1, the tumor was immunohistochemically stained with melan-A/MART-1, HMB-45, and S-100. Immunohistochemical staining with melan A/MART-1 was positive for the melanoma cells of the initially developed lesion and massively proliferated lesion (Figs. 4,) (c, ×100; d, ×400) (Oiso et al., 2010). Immunohistochemical staining with S-100 was positive for the melanoma cells of the initially developed lesion, but neative for the massively proliferated lesion except in one spot (Figs. 5,) (e, ×100; f, ×400) (Oiso et al., 2010). Immunohistochemical staining with HMB-45 was positive of for the melanoma cells of the initially developed lesion, but negative for the massively proliferated lesion (Figs. 6,) (g, ×100; h, ×400) (Oiso et al., 2010). Immunohistochemical staining is required for precisely diagnosing amelanotic melanoma.
Additional candidate markers for malignant melanoma are derived from melanocytic differentiation markers, proliferation markers, immunomodulatory markers, signaling molecules, and nerve growth factors and receptors (Ohsie et al., 2008). We recommend that a tumor or a macule suspected of being a malignant melanoma be initially stained with melan-A/MART-1, HMB-45 and S-100, and, for a more precise diagnosis, secondarily stained with various markers, including microphthalmia transcription factor (MITF), tyrosine hydroxylase, tyrosinase, and tyrosinase-related proteins 1 (TRP-1) and 2 (TRP-2).
2.3.2. Immunohistochemical staining to identify the damaged step in amelanotic melanoma
Immunohistochemical stains react with the expressing and specifically modified proteins. Staining may indicate the damaged step of melanogenesis. Fig. 7 illustrates the relationship of early melanogenesis and the proteins targeted for immunohistochemical staining.
Melan-A/MART-1 is a membrane protein localized in the endoplasmic reticulum,
This chapter summarizes the features of amelanotic melanoma on the basis of immunohistochemical staining with melanocyte-specific proteins as targets. The results show that the damaged step in melanogenesis in amelanotic melanoma can be evaluated histopathologically. The histopathological method is useful for at least two reasons: it describes the precise pathogenesis of amelanotic melanoma with intratumor heterogeneity, and it allows the sub-classification of the damaged step in melanogenesis to be determined.
We thank the patient and her daughter for signing the informed consent form allowing us to describe the patient’s case for scientific purposes.
Boissy R. E. Huizing M. Gahl W. A. 2006Biogenesis of melanosomes.in Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne J-P, eds: . 2nd edn. Blackwell Publishing Ltd, Oxford, 155 170.
Blessing K. Sanders D. S. Grant J. J. 1998Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. 2: 139 EOF 46 EOF.
Blum A. Jaworski S. Metzler G. Bauer J. 2004Lessons on dermoscopy: Dermoscopic pattern of hemosiderotic dermatofibroma. 10: 1354 EOF 1355 EOF.
Duggal R. Srinivasan R. 2010Primary amelanotic melanoma of the cervix: case report with review of literature. 3: 199-202.
Elmets C. A. Ceilley R. I. 1980Amelanotic melanoma as a pyogenic granuloma. 2: 161-167.
Ferrari A. Piccolo D. Fargnoli M. C. Biamonte A. S. Peris K. 2004Cutaneous amelanotic melanoma metastasis and dermatofibromas showing a dotted vascular pattern. 2: 164 EOF 165 EOF.
Gosselink C. P. Sindone J. L. Meadows B. J. Mohammadi A. Rosa M. 2009Amelanotic subungual melanoma: a case report. 2: 220 EOF 224 EOF.
Gualandri L. Betti R. Crosti C. 2009Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay. 3: 283 EOF 287 EOF.
Gupta R. K. Lallu S. 1997Cytodiagnosis of amelanotic metastatic malignant melanoma: an immunocytochemical study. 3: 238 EOF 41 EOF.
Hoashi T. Muller J. Vieira W. D. Rouzaud F. Kikuchi K. Tamaki K. Hearing V. J. 2006The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers. 30: 21198 EOF 208 EOF.
Hoashi T. Watabe H. Muller J. Yamaguchi Y. Vieira W. D. Hearing V. J. 2005MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. 14: 14006 EOF 16 EOF.
Holder J. E. Colloby P. S. Fletcher A. Camp R. D. 1996Amelanotic superficial spreading malignant melanoma mimicking Bowen’s disease. 3: 519 EOF 21 EOF.
Karimipour D. J. Lowe L. Su L. Hamilton T. Sondak V. Johnson T. M. Fullen D. 2004Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? 5759-764.
Kato H. Inoue Y. Ishihara T. Kageshita T. Ihn H. 2010Amelanotic malignant melanoma where primary lesion was discovered 5 years after metastasis in the lymph node. 8: 730 EOF 734 EOF.
Kanoh M. Amoh Y. Tanabe K. Maejima H. Takasu H. Katsuoka K. 2010Nestin is expressed in HMB-45 negative melanoma cells in dermal parts of nodular melanoma. 6: 505 EOF 511 EOF.
Kawakami Y. Eliyahu S. Delgado C. H. Robbins P. F. Rivoltini L. Topalian S. L. Miki T. Rosenberg S. A. 1994Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. 9: 3515 EOF 3519 EOF.
Khaled A. Hammami H. Fazaa B. Kourda N. Kamoun M. R. Ben Jilany. S. Zoghlami A. 2009Primary amelanotic anorectal melanoma: an uncommon neoplasia with poor prognosis. 3: 126-129.
Kushimoto T. Basrur V. Valencia J. Matsunaga J. Vieira W. D. Ferrans V. J. Muller J. Appella E. Hearing V. J. 2001A model for melanosome biogenesis based on the purification and analysis of early melanosomes. 19: 10698-10703.
Martires K. J. Capaldi L. Pattee S. F. Maloney M. E. Bordeaux J. S. 2010Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. 9: 1047 EOF 1048 EOF.
Matsuta M. Segawa I. Akasaka T. Kon S. Nara T. Minato S. 1990A case of subungual amelanotic malignant melanoma: an electron microscopic study of aberrant melanosomes. 4: 246 EOF 50 EOF.
Menzies S. W. Kreusch J. Byth K. Pizzichetta M. A. Marghoob A. Braun R. Malvehy J. Puig S. Argenziano G. Zalaudek I. Rabinovitz H. S. Oliviero M. Cabo H. Ahlgrimm-Siess V. Avramidis M. Guitera P. Soyer H. P. Ghigliotti G. Tanaka M. Perusquia A. M. Pagnanelli G. Bono R. Thomas L. Pellacani G. Langford D. Piccolo D. Terstappen K. Stanganelli I. Llambrich A. Johr R. 2008Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. 9: 1120-1127.
Notani K. Shindoh M. Yamazaki Y. Nakamura H. Watanabe M. Kogoh T. Ferguson M. M. Fukuda H. 2002Amelanotic malignant melanomas of the oral mucosa. 3: 195-200.
Ohsie S. J. Sarantopoulos G. P. Cochran A. J. Binder S. W. 2008Immunohistochemical characteristics of melanoma. 5: 433 EOF 444 EOF.
Oiso N. Yoshida M. Kawara S. Kawada A. 2010Amelanotic vulvar melanoma with intratumor histological heterogeneity. 6: 537 EOF 541 EOF.
Piccolo D. Lozzi G. P. Altamura D. Fargnoli M. C. Peris K. 2010Dermoscopic evolution of vascular pattern in two cases of amelanotic melanoma. 1: 83 EOF 85 EOF.
Sashiyama H. Tsujinaka Y. Hamahata Y. Tsutsumi O. Hoshino T. Minami Y. Tsunoda Y. Yano M. Sato Y. 2010Primary amelanotic malignant melanoma of the colon. 42Suppl 2: E163-164.
Terada, T. 2009Amelanotic malignant melanoma of the esophagus: report of two cases with immunohistochemical and molecular genetic study of KIT and PDGFRA. World J Gastroenterol Vol.215(No.21) 2679-2683.
Wain E. M. Stefanato C. M. Barlow R. J. 2008A clinicopathological surprise: amelanotic malignant melanoma. 3365-366.
Wang S. Thamboo T. P. Nga M. E. Zin T. Cheng A. Tan K. B. 2008c-kit positive amelanotic melanoma of the oesophagus: a potential diagnostic pitfall. 5: 527-530.
Yanagi Akiyama T. M. Kasai M. Yamakura M. Nishio M. Shimizu H. 2005Multiple skin metastases of amelanotic melanoma originating from the sinonasal mucosa. 554-555.
Yasuoka N. Ueda M. Ohgami Y. Hayashi K. Ichihashi M. 1999Amelanotic acral lentiginous malignant melanoma. 6: 370-372.
Zalaudek I. Argenziano G. Leinweber B. Citarella L. Hofmann-Wellenhof R. Malvehy J. Puig S. Pizzichetta M. A. Thomas L. Soyer H. P. Kerl H. 2004Dermoscopy of Bowen’s disease. 6: 1112-1116.
Zalaudek I. Ferrara G. Di Stefani A. Argenziano G. 2005Dermoscopy for challenging melanoma. How to raise the “red flag” when melanoma clinically looks benign. 1200-202.
Zubovits J. Buzney E. Yu L. Duncan L. M. 2004HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. 2: 217-223.